ABSTRACT This work aimed to compare the efficiency of two commercial recombinant bovine somatotropin (rbST) formulations on productive, metabolic, behavioral, and feeding parameters of mid-lactation Holstein cows. Eighteen secondiparous cows were randomly assigned to two groups to be treated with injectable rbST (rbST-Fast, Boostin ® , MSD Saúde Animal; and rbST-Slow, Lactotropin ® , Agener União Saúde Animal). Cows were rbST-treated during five cycles of 14 days each, totaling 70 days. Blood samples were collected thrice in each cycle to assess metabolic markers. Daily, automatic feeders and individual monitoring collars measured behavior and feed intake. Milk samples were collected weekly to evaluate milk composition and somatic cell count. The rbST-Fast group had higher milk production ( p = 0.03) and tended to present greater feed intake ( p = 0.07). In addition, animals treated with rbST-Fast had higher ( p < 0.01) concentrations of non-esterified fatty acids (NEFA) and tended ( p = 0.09) to have lower serum glucose values. As for the variation in body weight, cows treated with rbST-Fast lost approximately three times more weight ( p < 0.01) than rbST-Slow cows. Regarding milk components, cows from the rbST-Fast group produced milk with a higher lactose content ( p = 0.05). In conclusion, rbST-Fast treated cows produced more milk, had higher feed intake, and showed a higher degree of lipid mobilization, demonstrated through the higher body weight loss and higher NEFA concentrations. (rbST productive behavioral midlactation mid lactation rbSTFast, rbSTFast Fast, Fast (rbST-Fast Animal rbSTSlow, rbSTSlow Slow, Slow Animal. . Animal) rbSTtreated 1 7 markers Daily count 0.03 003 0 03 0.07. 007 0.07 07 0.07) addition 0.01 001 01 nonesterified non esterified (NEFA 0.09 009 09 values components 0.05. 005 0.05 05 0.05) conclusion mobilization 0.0 00 0.

RESUMO Esta pesquisa objetivou descrever a análise custo-benefício da adoção de terapia seletiva para mastite clínica a partir da identificação de patógenos por meio da cultura em placas na fazenda. Foi realizado um levantamento de casos clínicos de mastite no banco de dados de uma fazenda com 500 vacas Holandesas em lactação, durante o período de setembro de 2017 à outubro de 2019. Foram avaliadas as variáveis frequência de casos, principais patógenos identificados, custos com antibioticoterapia e descarte de leite foram, as quais foram comparados entre um ano antes (P1) e após (P2), à adoção da terapia seletiva na fazenda. Durante o período do estudo, foram identificados 599 casos de mastite clínica, sendo 361 em P1 e 238 em P2. O custo médio das terapias foi de US74,33 e US91,82 para P1 e P2. Considerando os dois anos de estudo, o custo estimado do tratamento da mastite clínica foi de US45.444,31, dos quais US27.559,97 foram gastos em P1 e US17.884,34 em P2. Com base na identificação dos tipos de patógenos associados à mastite clínica, a terapia seletiva demonstrou redução de custos já no primeiro ano de implantação. custobenefício benefício 50 lactação 201 2019 P (P1 P2, P2 , (P2) estudo 59 36 23 US7433 US US74 33 US74,3 US9182 US91 82 US91,8 US4544431 US45 444 31 US45.444,31 US2755997 US27 559 97 US27.559,9 US1788434 US17 884 34 US17.884,3 implantação 5 20 (P (P2 3 2 US743 US7 US74, US918 US9 8 US91, US454443 US4 44 US45.444,3 US275599 US2 55 9 US27.559, US178843 US1 88 US17.884, US45444 4 US45.444, US27559 US27.559 US17884 US17.884 US4544 US45.444 US2755 US27.55 US1788 US17.88 US454 US45.44 US275 US27.5 US178 US17.8 US45.4 US27. US17. US45.

ABSTRACT This research aims to describe the cost-benefit analysis of selective therapy adoption for clinical mastitis based on the identification of pathogens using on-farm culture system. A survey of clinical mastitis cases was carried out in the database of a dairy herd with 500 lactating Holstein cows, during the period of September 2017 to October 2019. Variables such as frequency of cases, main pathogens identified, costs with antibiotic therapies and milk disposal were evaluated and compared between one year before (P1) and after (P2), the farm's selective therapy adoption. During the study period, 599 cases of clinical mastitis were identified, 361 in P1 and 238 in P2. The average cost of therapies was US74.33 and US91.82 for P1 and P2. Considering the two years of the study, the estimated cost of treating clinical mastitis was US45,444.31, of which US$27,559.97 were spent in P1 and US17,884.34 in P2. Based on the result of the identification of the pathogen types associated with clinical mastitis, selective therapy demonstrated cost reduction already in the first year of implementation. costbenefit benefit onfarm farm system 50 cows 201 2019 identified P (P1 P2, P2 , (P2) farms s 59 36 23 US7433 US US74 33 US74.3 US9182 US91 82 US91.8 US4544431 US45 444 31 US45,444.31 US2755997 27 559 97 US$27,559.9 US1788434 US17 884 34 US17,884.3 implementation 5 20 (P (P2 3 2 US743 US7 US74. US918 US9 8 US91. US454443 US4 44 US45,444.3 US275599 55 9 US$27,559. US178843 US1 88 US17,884. US45444 4 US45,444. US27559 US$27,559 US17884 US17,884 US4544 US45,444 US2755 US$27,55 US1788 US17,88 US454 US45,44 US275 US$27,5 US178 US17,8 US45,4 US27 US$27, US17, US45, US2 US$27 US$2 US$